BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-6@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:Readout: Bristol-Myers Squibb (BMY) — Deucravacitinib [Nov 2026]
DESCRIPTION:Phase 3 primary completion: Efficacy and safety of Deucravaciti
 nib in adults with active Sjögren's Syndrome.\nSource: https://clinicaltr
 ials.gov/study/NCT05946941\nhttps://catalystbrief.girapphe.com/e/6?lang=en
 \nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/6?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
